Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

NCT01895127 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy

Conditions

Antibody-mediated Rejection
Humoral Rejection

Interventions

DRUG: Eculizumab
BIOLOGICAL: Immunoglobulin
PROCEDURE: Plasmapheresis

Sponsor

Brigham and Women's Hospital

Collaborators

[object Object]